Immutep: Granted Japanese patent for efti
- Biotech company Immutep has been granted a patent from the Japanese Patent Office for its eftilagimod alpha (efti) treatment
- This new patent, titled “Combined Preparations for the Treatment of Cancer,” also follows grants in Europe and Australia in 2019
- The patent also will protect the company’s intellectual property on efti and will expire in December 2034
- efti Immutep’s anti-cancer drug, which designed to treat metastatic breast cancer
- In a recent clinical trial, efti also shown to have a higher six-month progression-free survival rate over a placebo treatment
- Immutep is up 5.56 per cent on the market and shares are currently trading for 14.3 cents each
